Why the study?
Does combination therapy with zofenopril and nebivolol improve outcomes in patients with arterial hypertension and coronary heart disease?
Does combination therapy with zofenopril and nebivolol improve outcomes in patients with arterial hypertension and coronary heart disease?
Combination therapy with zofenopril and nebivolol is a pathogenetically justified approach for patients with concurrent arterial hypertension and coronary heart disease, offering both antihypertensive and anti-ischemic benefits.
Supports combined zofenopril-nebivolol in comorbid hypertension and CHD; leaves open confirmation in randomized outcome trials.
The leading positions in the treatment of patients with arterial hypertension (AH) and coronary heart disease (CHD) are held by angiotensin-converting enzyme (ACE) inhibitors and beta-adrenoblockers (BAB), which have demonstrated their effectiveness in terms of improved patients’ survival. In patients with AH and CHD, the rational, pathogenetic pharmacotherapy using a combination of an ACE inhibitor zofenopril and a highly cardio-selective and vasodilating BAB nebivolol demonstrates antihypertensive and antiischemic action, decreases the risk of potential adverse cardio-metabolic effects, reduces the severity of endothelial dysfunction, and, consequently, improves quality of life.
No takes yet. Share an insight, caveat, or question.
Морозова et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: